Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 17
2003 12
2004 14
2005 20
2006 19
2007 18
2008 19
2009 10
2010 11
2011 20
2012 14
2013 11
2014 21
2015 20
2016 16
2017 20
2018 25
2019 14
2020 17
2021 17
2022 10
2023 12
2024 9
2025 14
2026 11

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

333 results

Results by year

Filters applied: . Clear all
Page 1
The Lancet Commission on diabetes: using data to transform diabetes care and patient lives.
Chan JCN, Lim LL, Wareham NJ, Shaw JE, Orchard TJ, Zhang P, Lau ESH, Eliasson B, Kong APS, Ezzati M, Aguilar-Salinas CA, McGill M, Levitt NS, Ning G, So WY, Adams J, Bracco P, Forouhi NG, Gregory GA, Guo J, Hua X, Klatman EL, Magliano DJ, Ng BP, Ogilvie D, Panter J, Pavkov M, Shao H, Unwin N, White M, Wou C, Ma RCW, Schmidt MI, Ramachandran A, Seino Y, Bennett PH, Oldenburg B, Gagliardino JJ, Luk AOY, Clarke PM, Ogle GD, Davies MJ, Holman RR, Gregg EW. Chan JCN, et al. Among authors: seino y. Lancet. 2021 Dec 19;396(10267):2019-2082. doi: 10.1016/S0140-6736(20)32374-6. Epub 2020 Nov 12. Lancet. 2021. PMID: 33189186 Review. No abstract available.
[Hexokinase].
Nabe K, Seino Y. Nabe K, et al. Among authors: seino y. Nihon Rinsho. 2002 Jul;60 Suppl 7:542-7. Nihon Rinsho. 2002. PMID: 12238095 Review. Japanese. No abstract available.
Efficacy and safety of the sodium-glucose co-transporter-2 inhibitor empagliflozin in elderly Japanese adults (≥65 years) with type 2 diabetes: A randomized, double-blind, placebo-controlled, 52-week clinical trial (EMPA-ELDERLY).
Yabe D, Shiki K, Homma G, Meinicke T, Ogura Y, Seino Y; EMPA-ELDERLY Investigators. Yabe D, et al. Among authors: seino y. Diabetes Obes Metab. 2023 Dec;25(12):3538-3548. doi: 10.1111/dom.15249. Epub 2023 Aug 25. Diabetes Obes Metab. 2023. PMID: 37622398 Clinical Trial.
Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial.
Yamada Y, Katagiri H, Hamamoto Y, Deenadayalan S, Navarria A, Nishijima K, Seino Y; PIONEER 9 investigators. Yamada Y, et al. Among authors: seino y. Lancet Diabetes Endocrinol. 2020 May;8(5):377-391. doi: 10.1016/S2213-8587(20)30075-9. Lancet Diabetes Endocrinol. 2020. PMID: 32333875 Clinical Trial.
Understanding the incretin effect.
Seino Y. Seino Y. J Clin Endocrinol Metab. 2011 Apr;96(4):934-5. doi: 10.1210/jc.2011-0329. J Clin Endocrinol Metab. 2011. PMID: 21474688 No abstract available.
333 results